Ex-Baxalta Plant Gives Takeda First US Biologics Capacity
This article was originally published in PharmAsia News
Executive Summary
Newly independent Baxalta has decided that one its domestic manufacturing facilities is surplus to requirements and is selling a biologics plant to Takeda that will become the Japanese firm's first in-house production facility in the US.